As the U.S. Food and Drug Administration’s Center for Veterinary Medicine continues to progress in implementation of its Animal and Veterinary Innovation Agenda, the center is supporting a collaborative agreement to the Reagan-Udall Foundation for the FDA (the Foundation) to conduct a strengths, weaknesses, opportunities, and threats (SWOT) analysis.

In a continuation of progress towards the implementation of the AVIA, the FDA announced support for a collaboration agreement to the Reagan-Udall Foundation for the FDA.

The event was hosted by the Reagan-Udall Foundation for the FDA. While it didn’t center on psychedelic-assisted treatments only, many exchanged views on the topic.

Read more

In Silico Methods drive scientific innovation by leveraging computer simulation instead of biological testing.

Read more

Last Friday, the Reagan-Udall Foundation held a public meeting to discuss the advancement of treatments for PTSD, which includes psychedelics.

A new report from the Reagan-Udall Foundation for the FDA explores which parts of the rule are confusing to executives that are working to bring their companies into alignment with the rule.

New labels would inform consumer whether the products are high in added sugars, sodium or saturated fats.